Evrysdi - (0.75 mg/mL ; For Oral Solution)

Generic Name	Risdiplam	Innovator	Genentech, Inc.
Dosage	0.75 mg/mL ; For Oral Solution	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	EVRYSDI is a survival of motor neuron 2 (SMN2) splicing modifier indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
*****	*** \ *********	*** **, ****	*******	****	*** ****** *** ****
***** ******	*** \ *********	*** **, ****	*******	****	*** ****** *** ****

Chronology Of Events